Cardiac metabolic reprogramming by a nutritional intervention: High Fat diet for Heart Failure

Acronym : HF4HF

Call : CardInnov 2023

Topic

The heart is a unique organ that performs an incessant work to pump blood throughout the body. For this massive effort, it requires a very high supply of energy. Mitochondria are small components of the cells responsible for the production of energy. To produce energy, mitochondria from cardiac cells can use fuel of different origins (fats, glucose, proteins, etc). In normal circumstances, cardiac mitochondria use preferentially fats since they are more efficient in terms of quantify of energy produced. Recent data from our consortium has demonstrated that if the cardiac mitochondria switch the primary source of fuel (from fats to glucose), this results in a poor performance of the organ, which cannot supply the whole body with enough blood. This is known as heart failure. In experimental models of heart failure, we have demonstrated that a high fat diet is able to reverse the metabolic switch and make the cardiac cells mitochondria use again fats as the primary substrate to produce energy. This translates into a recovery of heart failure. In the present project, we plan to bring this concept to the human setting and perform a pilot clinical study where patients with heart failure are put in a dietary program consisting of high fat diet. The effect of this nutritional approach will be evaluated by state-of-the-art non-invasive imaging technology.

We will also perform studies in explanted hearts from patients with heart failure and in blood from experimental studies and patients. We will also perform additional experimental work in animal models of heart failure to study whether all fat-based diets exert the same effect on the heart. This project brings together a multidisciplinary team of cardiologists, experts in nutrition, imagers and industryen in HF patients

  • Coordinator:

    Borja IBÁÑEZ, Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P), Madrid, Spain

  • Partners:
    • Ruxandra Oana JURCUT, University of Medicine and Pharmacy "Carol Davila" Bucarest, Romania
    • Jean-Sébastien HULOT, INSERM PARIS, France
    • Pablo GARCIA PAVIA, Fundacion Investigacion Biomedica Hospital Universitario Puerta de Hierro (IIS) Majadahonda, Spain
    • FRANCESCO SOFI, UNIVERSITY OF FLORENCE FLORENCE, Italy
    • (*) Javier SÁNCHEZ-GONZÁLEZ, Philips Madrid, Spain
Back to index